Name | Raloxifene |
Synonyms | Evista RALOXAFINE Raloxifene [4-[2-(1-Piperidinyl) Ethoxy] Phenyl]methanone.HCL [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-y1][4-[2-(1-piperidinyl)ethoxy]phenyl]methamone [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl] ketone Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]- [6-hydroxy-2-(4-hydroxyphenyl)benzothiophen-3-yl]-[4-[2-(1-piperidyl)ethoxy]phenyl]methanone hydrochloride |
CAS | 84449-90-1 |
EINECS | 686-786-1 |
InChI | InChI=1/C28H27NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,30-31H,1-3,14-17H2 |
Molecular Formula | C28H27NO4S |
Molar Mass | 473.58 |
Density | 1.289±0.06 g/cm3(Predicted) |
Melting Point | 250-253°C |
Boling Point | 728.2±60.0 °C(Predicted) |
Water Solubility | 560μg/L at 25℃ |
Solubility | DMSO: 28mg/mL, soluble |
Appearance | solid |
Color | light yellow |
pKa | 8.83±0.15(Predicted) |
Storage Condition | Desiccate at +4°C |
Physical and Chemical Properties | Crystallization from acetone, melting point 143-147 °c. UV absorption maximum (ethanol):290nm (λ34000). Raloxifene Hydrochloride: C28H27NO4S? HCl. [8264000408]. Crystallization from methanol-water, melting point 258 °c. UV absorption maximum (ethanol):286NM (λ328 00). |
WGK Germany | 3 |
HS Code | 29349990 |
crystallized from acetone, melting point 143-147 °c. UV absorption maximum (ethanol);290nm(e34000).
2 (4-hydroxyphenyl) benzo [B] thiophene-6 monoalcohol is esterified with methanesulfonyl chloride to produce Diester with 4-(2-piperidinyl ethoxy) benzoyl chloride is subjected to acylation reaction, and raloxifene is obtained by hydrolysis.
It was developed by the U. S. Lily and company and was launched in the United States in January 1998. Estrogen receptor modulators, in the uterus and breast tissue showed antagonistic estrogen effect, inhibition of mammary epithelial and endometrial hyperplasia. In the aspect of bone lipid metabolism showed Excitatory effect, with the role of estrogen. The combination of raloxifene and calcium preparations can prevent bone loss, maintain bone density and reduce blood wax.